Recommendations for compounding medications for feeding tube administration

International Journal of Pharmaceutical Compounding

Volumn 14, Issue 4, 2010, Pages 276-282

  Klang, Mark ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CIPROFLOXACIN; ITRACONAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; OFLOXACIN; OMEPRAZOLE; PENTOXIFYLLINE; PHENYTOIN; PROTON PUMP INHIBITOR; WARFARIN;

CLINICAL TRIAL; DIAPHORESIS; DIZZINESS; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG STABILITY; ENTERIC COATED TABLET; ENTERIC FEEDING; FEEDING APPARATUS; FOOD; FOOD DRUG INTERACTION; HEADACHE; HUMAN; JEJUNOSTOMY TUBE; NASOGASTRIC TUBE; NAUSEA; REVIEW; SIDE EFFECT; STOMACH TUBE; VOMITING;

EID: 77957844099     PISSN: 10924221     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Cappell MS, Scarpa PJ, Nadler S et al. Complications of nasoenteral tubes. Intragastric tube knotting and intragastric tube breakage. J Clin Gastroenterol 1992; 14(2): 144-147.
2. Morris HH. Nasogastric intubation: A potentially knotty problem. JAMA 1977; 237(14): 1432.
3. Butsch JL. A knotty problem with a feeding jejunostomy tube. Arch Surg 1986; 121(6): 736.
4. Marcuard SP, Stegall KS. Unclogging feeding tubes with pancreatic enzyme. JPEN J Parenter Enteral Nutr 1990; 14(2): 198-200.
5. Hofstetter J, Allen LV Jr. Causes of non-medication-induced nasogastric tube occlusion. Am J Hosp Pharm 1992; 49(3): 603-607.
6. Mateo MA. Nursing management of enteral tube feedings. Heart Lung 1996; 25(4): 318-323.
7. Chang WK, McClave SA, Hsieh CB et al. Gastric residual volume (GRV) and gastric contents measurement by refractometry. JPEN J Parenter Enteral Nutr 2007; 31(1): 63-68.
8. Powell KS, Marcuard SP, Farrior ES et al. Aspirating gastric residuals causes occlusion of small-bore feeding tubes. JPEN J Parenter Enteral Nutr 1993; 17(3): 243-246.
9. Jabbar A, McClave SA. Pre-pyloric versus post-pyloric feeding. Clin Nutr 2005; 24(5): 719-726.
10. Kristl A. Membrane permeability in the gastrointestinal tract: The interplay between microclimate pH and transporters. Chem Biodivers 2009; 6(11): 1923-1932.
11. Lu AT, Frisella ME, Johnson KC. Dissolution modeling: Factors affecting the dissolution rates of polydisperse powders. Pharm Res 1993; 10(9): 1308-1314.
12. [No author listed.] Wikipedia. Absorption. [Wikipedia Website.] January 29, 2010. Available at: http://en.wikipedia.org/wiki/Absorption- (pharmacokinetics). Accessed May 3, 2010.
13. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004; 21(2): 201-230.
14. James LP, Nichols MH, King WD. A comparison of cathartics in pediatric ingestions. Pediatrics 1995; 96(2 Pt 1): 235-238.
15. Gattuso JM, Kamm MA. Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Saf 1994; 10(1): 47-65.
16. Madigan SM, Courtney DE, Macauley D. The solution was the problem. Clin Nutr 2002; 21(6): 531-532.
17. Benya R, Layden TJ, Mobarhan S. Diarrhea associated with tube feeding: The importance of using objective criteria. J Clin Gastroenterol 1991; 13(2): 167-172.
18. Edes TE, Walk BE, Austin JL. Diarrhea in tube-fed patients: Feeding formula not necessarily the cause. Am J Med 1990; 88(2): 91-93.
19. Estoup M. Approaches and limitations of medication delivery in patients with enteral feeding tubes. Crit Care Nurse 1994; 14(1): 68-72.
20. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology 1982; 32(5): 570-572.
21. Bauer LA, Edwards WA, Dellinger EP et al. Importance of unbound phenytoin serum levels in head trauma patients. J Trauma 1983; 23(12): 1058-1060.
22. Martin JE, Lutomski DM. Warfarin resistance and enteral feedings. JPEN J Parenter Enteral Nutr 1989; 13(2): 206-208.
23. Wright DH, Pietz SL, Konstantinides FN et al. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. JPEN J Parenter Enteral Nutr 2000; 24(1): 42-48.
24. Au Yeung SC, Ensom MH. Phenytoin and Enteral Feedings: Does evidence support an Interaction? Ann Pharmacother 2000; 34(7-8): 896-905.
25. Doak KK, Haas CE, Dunnigan KJ et al. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. Pharmacotherapy 1998; 18(3): 637-645.
26. Krueger KA, Garnett WR, Comstock TJ et al. Effect of two administration schedules of an enteral nutrition formula on phenytoin bioavailability. Epilepsia 1987; 28(6): 706-712.
27. Marvel ME BJ. Comparative effects of an elemental and complex enteral feeding formulation on the absorption of phenytoin suspension. JPEN J Parenter Enteral Nutr 1991; 15(3): 316-318.
28. Newton DW, Kluza RB. Prediction of phenytoin solubility in intravenous admixtures: physicochemical theory. Am J Hosp Pharm 1980; 37(12): 1647-1651.
29. Burstein AH, Cox DS, Mistry B et al. Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats. Epilepsy Res 1999; 34(2-3): 129-133.
30. Kafedjiiski K, Föger F, Hoyer H et al. Evaluation of in vitro enzymatic degradation of various thiomers and cross-linked thiomers. Drug Dev Ind Pharm 2007; 33(2): 199-208.
31. Klang MG. Model to Measure Phenytoin Dissolution Interaction with Enteral Nutrition. Poster presentation at the 2009 ESPEN conference in Vienna, Austria. P-238.
32. Dickerson RN. Warfarin resistance and enteral tube feeding: A vitamin K-independent interaction. Nutrition 2008; 24(10): 1048-1052.
33. Landau J, Moulda RF. Warfarin resistance caused by vitamin K in intestinal feeds. Med J Aust 1982; 2(6): 263-264.
34. Illum L, Bundgaard H. Sorption of drugs by plastic infusion bags. Int J Pharm 1982; 10(4): 339-351.
35. Nyffeler MS. Ciprofloxacin Use in the Enterally Fed Patient. Nutr Clin Pract 1999; 14(April): 73-77.
36. Yuk JH, Nightingale CH, Sweeney KR et al. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding. Antimicrob Agents Chemother 1989; 33(7): 1118-1120.
37. Yuk JH, Nightingale CH, Quintiliani R et al. Absorption of ciprofloxacin administered through a nasogastric or a nasoduodenal tube in volunteers and patients receiving enteral nutrition. Diagn Microbiol Infect Dis 1990; 13(2): 99-102.
38. Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother 1996; 40(1): 6-10.
39. Mueller BA, Brierton DG, Abel SR et al. Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1994; 38(9): 2101-2105.
40. Cleary JD, Evans PC, Hikal AH et al. Administration of crushed extended-release pentoxifylline tablets: Bioavailability and adverse effects. Am J Health Syst Pharm 1999; 56(15): 1529-1534.
41. Jacobson PA, Johnson CE, Walters JR. Stability of itraconazole in an extemporaneously compounded oral liquid. Am J Health Syst Pharm 1995; 52(2): 189-191.
42. Kintzel PE, Rollins CJ, Yee WJ et al. Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogeneic bone marrow transplant recipients. Ann Pharmacother 1995; 29(2): 140-143.
43. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997; 52(3): 235-237. (Pubitemid 27278380)
44. Cohen MR. "Do Not Crush" list. Nursing 2007 2007; 37(7): 12.
45. Howden CW. Review article: immediate-release proton-pump inhibitor therapy - potential advantages. Aliment Pharmacol Ther 2005; 22 Suppl 3: 25-30.
46. Horn JR, Howden CW. Review article: Similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther 2005; 22 Suppl 3: 20-24.
47. Devlin JW, Bakshi A, Bungay K et al. An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube. Aliment Pharmacol Ther 2006; 24(11-12): 1603-1611.
48. Prevacid [package insert]. Deerfield, IL: Takeda Pharmaceuticals Company.